NEW YORK (GenomeWeb News) – Roche today reported that first-quarter revenues for its diagnostics division grew 7 percent to CHF 2.52 billion ($2.38 billion), led by strong sales for its applied science and tissue diagnostics businesses, while sales for its molecular diagnostics products were flat year over year.
The Swiss pharmaceuticals, diagnostics, and research products giant reported 8 percent revenue growth for its professional diagnostics products to CHF 1.17 billion, while sales for its diabetes care diagnostics were up 4 percent at CHF 708 million.
Sales for the firm's applied science business jumped 15 percent year over year to CHF 226 million, while sales of its tissue diagnostics products increased 13 percent to CHF 120 million. Roche said that applied science sales were driven by strong demand for its MagNA Pure and LightCycler product lines for sample preparation and quantitative PCR analysis and 40 percent growth for its microarray business.
Its molecular diagnostics sales were flat year over year at CHF 294 million. However, Roche said that initial uptake for its cobas 4800 system — a fully-automated mid- to high-throughput molecular diagnostics instrument launched at the end of 2009 — has been "very encouraging."
The current menu for the new system includes tests for Chlamydia trachomatis and Neisseria gonorrhoeae, as well as a genotyping test for human papillomavirus. Roche added that it plans to file for US clearance of the HPV test in mid-year.
Overall, Roche reported first-quarter sales of CHF 12.25 billion, up 6 percent from Q1 2009 revenues of CHF 11.58 billion.